Xi Wang, Rui Wang, Fang Lin, Ke Dong, Ping Gao, Hui-Zhong Zhang
Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
J Cancer Res Clin Oncol. 2009 Jun;135(6):837-46. doi: 10.1007/s00432-008-0520-1. Epub 2008 Nov 26.
Stathmin (Oncoprotein18), a ubiquitous and highly conserved 19-kDa cytosolic phosphoprotein, has been reported to play a critical role in mitosis and possibly other cellular processes, which is associated with tumor carcinogenesis and development. The purpose of this study was to examine the involvement of stathmin in human cervical carcinogenesis and to evaluate its prognostic significance in human cervical carcinoma.
Using semiquantitative RT-PCR and Western blotting, we detected the expression of stathmin in human normal cervical epithelial cell line, immortalized cervical epithelial cell lines, and cervical carcinoma cell lines. Additionally, we also detected the expression of stathmin protein in 15 cases of cervical carcinoma tissues and adjacent non-carcinomous margin tissues. Furthermore, specimens from 148 patients with different grade and stage cervical carcinoma were investigated by immunohistochemistry for stathmin expression. Correlations between the expression of stathmin and various clinicopathological factors were studied, while statistical analyses were performed to evaluate prognostic and diagnostic associations.
The levels of stathmin mRNA and protein expression were significantly higher in cervical carcinoma cells and immortalized cervical epithelial cells than in normal cervical epithelial cells (P < 0.05). Moreover, Western blotting revealed high stathmin protein expression in 73.3% (11/15) cervical carcinoma tissues, while stathmin were overexpressed in tumor tissues as compared with adjacent non-carcinomous margin samples (P = 0.017). In addition, immunohistochemical staining revealed stathmin immunoreactivity in 81.1% (120/148) of cervical carcinoma tissues and high stathmin expression was significantly correlated with clinical stage (P = 0.006), T classification (P = 0.012), regional lymph node metastasis (P = 0.005) and hematogenous metastasis (P = 0.021). Kaplan-Meier analysis showed that high stathmin positivity was significantly associated with a shorter survival time (P < 0.001). Clinical stage (P = 0.0022), T classification (P = 0.0035), regional lymph node (P = 0.0008) or hematogenous metastasis (P = 0.0015) were also associated with survival time. Furthermore, by Cox multivariate analysis, only lymph node (P = 0.0052) or hematogenous metastasis (P = 0.0046) maintained their significance as independent prognostic factors, although stathmin was not an independent prognostic factor (risk ratio: 1.45; P = 0.0624).
Stathmin expression correlates with cervical carcinogenesis and tumor progression. This molecule is a valuable prognostic marker in patients with cervical carcinoma.
Stathmin(癌蛋白18)是一种普遍存在且高度保守的19 kDa细胞溶质磷蛋白,据报道其在有丝分裂以及可能的其他细胞过程中发挥关键作用,这与肿瘤的发生和发展相关。本研究旨在探讨Stathmin在人类宫颈癌发生中的作用,并评估其在人类宫颈癌中的预后意义。
我们运用半定量逆转录聚合酶链反应(RT-PCR)和蛋白质免疫印迹法,检测了Stathmin在人正常宫颈上皮细胞系、永生化宫颈上皮细胞系和宫颈癌细胞系中的表达。此外,我们还检测了15例宫颈癌组织及相邻非癌边缘组织中Stathmin蛋白的表达。进一步地,采用免疫组织化学方法对148例不同分级和分期的宫颈癌患者标本进行Stathmin表达研究。研究了Stathmin表达与各种临床病理因素之间的相关性,并进行统计学分析以评估预后和诊断相关性。
宫颈癌细胞和永生化宫颈上皮细胞中Stathmin mRNA和蛋白表达水平显著高于正常宫颈上皮细胞(P < 0.05)。此外,蛋白质免疫印迹显示73.3%(11/15)的宫颈癌组织中Stathmin蛋白高表达,与相邻非癌边缘样本相比,肿瘤组织中Stathmin过表达(P = 0.017)。另外,免疫组织化学染色显示81.1%(120/148)的宫颈癌组织中有Stathmin免疫反应性,且Stathmin高表达与临床分期(P = 0.006)、T分级(P = 0.012)、区域淋巴结转移(P = 0.005)和血行转移(P = 0.021)显著相关。Kaplan-Meier分析表明,Stathmin高阳性与较短的生存时间显著相关(P < 0.001)。临床分期(P = 0.0022)、T分级(P = 0.0035)、区域淋巴结(P = 0.0008)或血行转移(P = 0.0015)也与生存时间相关。此外,通过Cox多因素分析,尽管Stathmin不是独立预后因素(风险比:1.45;P = 0.0624),但只有淋巴结(P = 0.0052)或血行转移(P = 0.0046)作为独立预后因素仍具有统计学意义。
Stathmin表达与宫颈癌发生及肿瘤进展相关。该分子是宫颈癌患者有价值的预后标志物。